Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy

Modern Pathology

Volumn 11, Issue 9, 1998, Pages 892-899

  Rakozy, Christiane ^a   Grignon, David J ^a,c   Sarkar, Fazlul H ^a   Sakr, Wael A ^a   Littrup, Peter ^b   Forman, Jeffrey ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Apoptosis; Bcl 2; Biopsy; Carcinoma; Immunohistochemistry; p21; p53; Prostate; Radiation therapy; Tumor suppressor genes

Indexed keywords

PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031691437     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Forman JD, Oppenheim T, Liu H, Montie J, McLaughlin PW, Porter AW. Frequency of residual neoplasm in the prostate following three-dimensional conformal radiotherapy. Prostate 1993;23:235-43.
2. Pilepich MV, Krall JM, Al-Sarraf M, John MJ, Doggett RLS, Sause WT, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45: 616-23.
3. Dugan TC, Shipley WU, Young RH, Verhey LJ, Althausen AF, Heney NM, et al. Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels. J Urol 1991;146:1313-6.
4. Crook J, Robertson S, Collin G, Zaleski V, Esche B. Clinical relevance of transrectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1993;27:31-7.
5. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;15:1013-21.
6. Harris DR, Savill J. Apoptosis and the prostate. Br J Urol 1995;75(Suppl 1):27-33.
7. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251-65.
8. Forman JD, Duclos M, Shamsa F, Porter AT, Orton C. Hyperfractionated conformal radiotherapy in locally advanced prostate cancer: results of a dose escalation study. Int J Radiat Oncol Biol Phys 1996;34:655-62.
9. Littrup PJ, Sparschu RA. Transrectal ultrasound and prostate cancer risks: the "tailored" prostate biopsy. Cancer 1995; 75(Suppl):1805-13.
10. Schneider C, Grignon D, Sakr W, Sarkar F, Littrup P, Long D, et al. Pathologic and biologic features of positive post-radiation therapy biopsies as predictors of treatment failure in prostate cancer [abstract]. Mod Pathol 1997;10:89A.
11. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997;89:158-65.
12. WAF-1/CIP1 and p53 expression in pancreatic adenocarcinoma. Cancer 1997;80:372-81.
13. Colombel M, Summans F, Gil S, O'Toole LM, Chopin D, Benson M, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancer. Am J Pathol 1993;143:390-400.
14. American Society for Therapeutic Radiology, Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37:1035-41.
15. Prestidge BR, Kaplan I, Cox RS, Bagshaw MA. The clinical significance of a positive post-irradiation prostatic biopsy without metastases. Int J Radiat Oncol Biol Phys 1992;24: 403-8.
16. Scardino PT, Wheeler TM. Prostate biopsy after irradiation therapy for prostatic cancer. Urology 1985;5:39-46.
17. Scardino PT, Frankel JM, Wheeler TM, Meacham RB, Hoffman GS, Seale C, et al. The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. J Urol 1986;135:510-6.
18. Lu Q, Abel P, Foster C, Lalani E. bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol 1996;27:102-10.
19. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-76.
20. Bubendorf L, Sauter G, Moch H, Jordan P, Bloechlinger A, Gasser T, et al. Prognostic significance of bcl-2 in clinically localized prostate cancer. Am J Pathol 1996;148:1557-65.
21. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-45.
22. Berchem GJ, Bosseler M, Sugars LY, Voeller J, Zeitlin S, Gelman EP. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 1995; 55:735-8.
23. McDonnell TJ, Tronocoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
24. Bostwick DG, Egbert BM, Fajardo LF. Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol 1982;6: 541-51.
25. Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH, Thompson CB, et al. Multiple bcl-2 family members demonstrate selective dimerizations with box. Proc Natl Acad Sci U S A 1995; 92:7834-8.
26. Carson DA, Lois A. Cancer progression and p53. Lancet 1995;346:1009-11.
27. Ewen ME, Miller S. p53 and translational control. Biochim Biophys Acta 1996;1242:181-4.
28. Cox LS, Lane DP. Tumour suppressors, kinases, and clamps: how p53 regulates the cell cycle response to DNA damage. Bioassays 1995;17:501-8.
29. Girinsky T, Koumenis C, Graeber TG, Peehl DM, Giaccia AJ. Attenuated response of p53 and p21 in primary culture of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res 1995;55:3726-31.
30. Linke SP, Clarkin KC, Wahl GM. p53 mediates permanent arrest over multiple cell cycles in response to γ irradiation. Cancer Res 1997;57:1171-9.
31. Prendergast NJ, Atkins MR, Schatte EC, Paulson DF, Walther PJ. p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. J Urol 1996;155:1685-92.
32. WAF1/CIP1 -/- human cancer cells. Cancer Res 1996;56:2250-5.
33. El-Deiry WF, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent J, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
34. Akashi M, Hachiya M, Yoshiaki O, Spirin K, Suzuki G, Koeffler HP. Irradiation induces WAF1 expression through a p53-independent pathway in KG-1 cells. J Biol Chem 1995;270: 19181-7.
35. WAF-/CIP1 protects against p53-mediated apoptosis of human melanoma cells. Oncogene 1997;4:929-35.
36. Adsay V, Sakr W, Grignon D, Frank J, Crissman J, Sarkar F. Distribution of WAF1 (p21) in normal and neoplastic prostate tissue. J Urol Pathol 1998 (in press).